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Background
Postnatal survival is dependent upon successful transition
of the pulmonary circulation at birth. Persistent pulmo-
nary hypertension of the newborn (PPHN) is a clinical
syndrome that is characterized by the failure to achieve or
sustain a marked reduction of pulmonary vascular resist-
ance (PVR) after delivery. High PVR causes extra-pulmo-
nary right-to-left shunt, leading to profound hypoxemia,
asphyxia and significant morbidity and mortality. Past
studies have shown that NO-cGMP signaling contributes
significantly to the normal fall in PVR at birth, and that
decreased NO production or activity contributes to PPHN.
Multicenter studies have shown that inhaled NO is effec-
tive in the treatment of clinical PPHN, but nearly 40% of
newborns with PPHN fail to respond to iNO therapy.
These findings suggest that additional therapies are essen-
tial for enhancing NO-cGMP signaling and improving
outcomes of neonates with severe PPHN. Since recent
studies demonstrated increased oxidative stress in experi-
mental PPHN, we hypothesized that impaired NO
responsiveness in PPHN may be due to decreased soluble
guanylate cyclase (sGC) activity due to oxidation. Cinaci-
guat (BAY 58-2667) is a novel sGC activator that causes
vasodilation even in the presence of oxidized heme, but
its hemodynamic effects in the perinatal lung are
unknown. Therefore, we performed a series of physiologic
studies in chronically-prepared, late gestation fetal lambs.
Additional in vitro studies were performed with isolated
pulmonary artery smooth muscle cells (SMC) from nor-
mal and PPHN lambs.
Results
We found that in the normal fetus, cinaciguat (0.1 to 100
mcg over 10 min) caused dose-related increases in pulmo-
nary blood flow greater than 4-fold above baseline values
and reduced PVR by 80%. Treatment with ODQ, an sGC
oxidizing inhibitor, enhanced cinaciguat-induced pulmo-
nary vasodilation by over 150%. The pulmonary vasodila-
tor effect of cinaciguat was prolonged, decreasing PVR for
more than 1.5 hours after brief intrapulmonary infusion.
In vitro stimulation of fetal pulmonary artery SMC with
cinaciguat after ODQ treatment demonstrated a 14-fold
increase in cGMP in comparison without ODQ. We fur-
ther studied the pulmonary vascular effects of cinaciguat
in fetal sheep with chronic pulmonary hypertension after
partial ligation of the ductus arteriosus (PPHN). We
found that in contrast with the loss of acetylcholine-
induced pulmonary vasodilation 5 days after surgery, the
cinaciguat response persisted and was enhanced in PPHN
lambs. After cesarean-section delivery and mechanical
ventilation, neonatal lambs with PPHN demonstrated
markedly impaired vasodiliation to inhaled NO (20 and
40 ppm). In contrast, brief infusion of cinaciguat caused
marked and prolonged pulmonary vasodilation.
Conclusion
Overall, these findings suggest that oxidized sGC contrib-
utes to the pathophysiology of PPHN, and that treatment
with cinaciguat, an sGC activator, may provide a novel
strategy in refractory PPHN.
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